InsiderPulseNo transactions found.
No financial data available for ARWR.
Company may not file with SEC or CIK is unresolved.
Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events
The Bull Case For Arrowhead Pharmaceuticals (ARWR) Could Change Following Australian Approval Of REDEMPLO For FCS
Arrowhead (ARWR) Rated Buy on Metabolic Pipeline Potential
Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS)
IgA Nephropathy Market Forecast to 2036: Novel Therapies and Key Growth Drivers Fuel Expansion | DelveInsight
Sanofi, Arrowhead, Novartis among winners of EU recommendations this week
Regulatory round-up: Novartis, Sanofi and Arrowhead secure CHMP blessings
Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe
This Biotech Stock Is Up 460% Over the Past Year. Why Analysts See It Rising Higher.
Arrowhead upgraded at Morgan Stanley on upcoming catalysts
Arrowhead Pharmaceuticals: Transition Phase With Moderate Upside Ahead
Revolution, Ascendis, Arrowhead among RBC’s top M&A candidates in biotech